# Verastem, Inc.: overview VSTM · Nasdaq · CIK 1526119 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vstm.md) · [Financials](/companies/vstm/financials.md) · [Filings](/companies/vstm/filings.md) · [Insiders](/companies/vstm/insiders.md) Latest reported revenue: [$40.1m](/filings/0001104659-26-092007.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-092007). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0 d](/filings/0001558370-24-014640.md) | [0.0 d](/filings/0001558370-25-003372.md) | not reported | [2.1](/filings/0001104659-26-092007.md) | [11.2](/filings/0001104659-25-106279.md) | [17.5 d](/filings/0001104659-26-023444.md) | [18.7](/filings/0001104659-26-057114.md) | [40.1](/filings/0001104659-26-092007.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(2047.9%)](/filings/0001104659-26-092007.md) | [(362.2%)](/filings/0001104659-25-106279.md) | [(236.5%) d](/filings/0001104659-26-023444.md) | [(240.5%)](/filings/0001104659-26-057114.md) | [(81.6%)](/filings/0001104659-26-092007.md) | | Net margin | % | not reported | not reported | not reported | [(1213.6%)](/filings/0001104659-26-092007.md) | [(876.3%)](/filings/0001104659-25-106279.md) | [(187.7%) d](/filings/0001104659-26-023444.md) | [(196.0%)](/filings/0001104659-26-092007.md) | [(86.5%)](/filings/0001104659-26-092007.md) | | Diluted EPS | $ per share | [(0.60)](/filings/0001104659-25-106279.md) | not reported | [(0.96)](/filings/0001104659-26-057114.md) | [(0.62)](/filings/0001104659-26-092007.md) | [(1.35)](/filings/0001104659-25-106279.md) | not reported | [(0.46)](/filings/0001104659-26-057114.md) | [(0.35)](/filings/0001104659-26-092007.md) | | Free cash flow | $m | [(23.8) d](/filings/0001104659-25-106279.md) | [(25.1) d](/filings/0001104659-26-023444.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.1](/filings/0001558370-23-003738.md) | [2.6](/filings/0001558370-25-003372.md) | not reported | [10.0](/filings/0001558370-25-003372.md) | [30.9](/filings/0001104659-26-023444.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2991.2%)](/filings/0001558370-24-003250.md) | [(2809.6%)](/filings/0001558370-25-003372.md) | not reported | [(1149.6%)](/filings/0001104659-26-023444.md) | [(550.3%)](/filings/0001104659-26-023444.md) | | Net margin | % | [(3468.1%)](/filings/0001558370-24-003250.md) | [(2843.3%)](/filings/0001558370-25-003372.md) | not reported | [(1306.4%)](/filings/0001104659-26-023444.md) | [(677.6%)](/filings/0001104659-26-023444.md) | | Diluted EPS | $ per share | [(4.90)](/filings/0001558370-24-003250.md) | [(4.57)](/filings/0001558370-25-003372.md) | [(3.96)](/filings/0001104659-26-023444.md) | [(3.66)](/filings/0001104659-26-023444.md) | [(3.02)](/filings/0001104659-26-023444.md) | | Free cash flow | $m | [(53.7)](/filings/0001558370-24-003250.md) | not reported | not reported | [(105)](/filings/0001104659-26-023444.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vstm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $35.1m | 9,192,447 | | Added +2,997,522 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $26.8m | 7,024,000 | | Added +2,432,000 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $25.3m | 6,635,793 | | Added +59,487 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $21.9m | 5,740,850 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $19.6m | 5,133,859 | | Added +1,617,208 | | [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $15.2m | 3,986,509 | | Added +1,848,034 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $14.7m | 3,851,508 | | Added +528,738 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $13.7m | 3,584,820 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $13.7m | 3,584,820 | | Unchanged | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $12.8m | 3,349,627 | | Added +47,327 | ## Recent filings [All 1,040 filings](/companies/vstm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-14 | 17:21 ET | [8-K](/filings/0001104659-26-115880.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-115880 | | 2026-10-14 | 06:08 ET | [8-K](/filings/0001104659-26-115687.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-115687 | | 2026-08-07 | 19:33 ET | [8-K](/filings/0001104659-26-092216.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-092216 | | 2026-08-06 | 16:29 ET | [8-K](/filings/0001104659-26-092058.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-092058 | | 2026-08-06 | 16:12 ET | [10-Q](/filings/0001104659-26-092007.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092007 | | 2026-06-23 | 16:02 ET | [8-K](/filings/0001104659-26-076809.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-076809 | | 2026-06-17 | 08:52 ET | [8-K](/filings/0001104659-26-074915.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-074915 | | 2026-05-26 | 08:15 ET | [8-K](/filings/0001104659-26-066026.md) | 5.07 Shareholder vote results | 0001104659-26-066026 | | 2026-05-07 | 16:11 ET | [8-K](/filings/0001104659-26-057126.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-057126 | | 2026-05-07 | 16:07 ET | [10-Q](/filings/0001104659-26-057114.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057114 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-023444.md), filed Mar 4, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1526119 - Tickers: VSTM - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: MA - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:42 ET. No prices; not investment advice.